Pfizer To Re-Do Celebrex GI Outcome Study After Pharmacia Merger
Executive Summary
Pfizer's post-merger plans for Celebrex include a second gastrointestinal outcomes study to demonstrate a safety benefit for the COX-2 inhibitor
You may also be interested in...
Merck Vioxx Formulary Status Retained Since VIGOR GI, CV Label Change
Vioxx has retained key formulary positions and added new accounts since the VIGOR label change, Merck Human Health President-Europe Per Wold-Olsen said during the company's annual business briefing in Whitehouse Station, N.J., Dec. 10
Merck Vioxx Formulary Status Retained Since VIGOR GI, CV Label Change
Vioxx has retained key formulary positions and added new accounts since the VIGOR label change, Merck Human Health President-Europe Per Wold-Olsen said during the company's annual business briefing in Whitehouse Station, N.J., Dec. 10
Bear Stearns Healthcare Conference In Brief
One Swiss pharma company?: Novartis continues "to indicate to Roche that it might be a good idea for us to sit down and talk and I think as late as last Sunday, the Roche CEO continues to say that it's absolutely out of the question and not on the table," General Manager Kurt Graves says during Bear Stearns healthcare conference in New York City Sept. 17. "I would say it's remained consistent for over a year." Novartis' purchase of a 20% stake in Roche a year ago sparked rumors that Novartis was interested in partnering with its Swiss neighbor (1"The Pink Sheet" May 14, 2001, p. 11)...